The drug, called olaparib, specifically targets hereditary cancer caused by faulty BRCA1 and BRCA2 genes. The small scale patient trial has shown remarkable benefit for patients with breast, ovarian and prostate cancer. The trial was carried out by The Institute of Cancer Research with the Royal Marsden Hospital, working with pharmaceutical company AstraZeneca, with results published in the New England Journal of Medicine on 9 July 2009.
More...
Linear Mode
